Evidence strength for the context described on this page.
PEPTIDE ATLAS / SEXUAL & REPRODUCTIVE / KISSPEPTIN-10
InvestigationalEarly human
Kisspeptin-10
ALSO KNOWN ASKP-10
A reproductive-signaling peptide under study—not a consumer libido or fertility protocol.
01CATEGORYSexual & reproductive
02REGULATORY STATUSInvestigational
03COMMON ROUTEIntravenous or subcutaneous in research; subcutaneous in clinic marketing
04DOSE BASISHuman research + reported clinic use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Kisspeptin-10 is.
A short active fragment of kisspeptin that stimulates the hypothalamic reproductive axis. Clinical research includes fertility, hormone release and sexual/brain-response questions.
HOW IT IS THOUGHT TO WORK
Activates KISS1R, stimulating GnRH and downstream LH/FSH signaling when the reproductive axis is responsive.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Can trigger reproductive-hormone signaling in controlled research
- Investigational fertility applications
- General libido enhancement
- Treatment of infertility outside specialist protocols
- Safe chronic use
- An established male or female wellness dose
Evidence grade: Early human. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Human research + reported clinic useBest human-research range: IV boluses of 0.01–3 mcg/kg in healthy men; subcutaneous research also produced prolonged LH responses. Current clinics commonly publish 100–300 mcg subcutaneously per injection, once daily, every other day or a few times weekly. The clinic range is not FDA approved or validated as a general fertility, libido or testosterone protocol.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Clinic schedules vary from a single injection to once daily or 2–3 times weekly for 4–12 weeks. Research schedules are protocol- and diagnosis-specific.
- How to interpret it
- Men and women should not be treated as interchangeable for reproductive-axis dosing. Repeated kisspeptin exposure can cause tachyphylaxis, and fertility protocols require reproductive-endocrinology monitoring.
ACTUAL HUMAN DOSES REPORTED IN THE RECORD
Research regimens may use different routes, diagnoses, formulations and monitoring. They cannot automatically be converted into a general protocol.
- Healthy-men dose-response study: IV bolus doses from 0.01–3 mcg/kg.
- Human subcutaneous studies used protocol-specific weight-based doses and measured LH/FSH responses under intensive monitoring.
- Route
- Intravenous or subcutaneous in research; subcutaneous in clinic marketing
- Duration
- Protocol-defined; reported clinic cycles vary from a single dose to 4–12 weeks
- Men & women
- Response depends on sex, cycle phase, gonadal status, reproductive diagnosis and concurrent fertility treatment; no universal sex-specific regimen exists.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- LH, FSH and sex-steroid response
- Ovulation or assisted-reproduction outcomes
- Ovarian response and specialist safety monitoring
SAFETY
Risks, red flags and reasons to avoid it.
- Hormonal overstimulation
- Unknown long-term effects
- Immunogenicity and impurities in compounded products
- Potential interference with fertility protocols
- Self-treatment
- Pregnancy outside research
- Use without reproductive-endocrinology oversight
- Unverified compounded product
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Clinical research and limited unapproved marketing; no FDA-approved kisspeptin-10 drug.
A peptide that moves a hormone marker can be biologically active without being a proven fertility or desire treatment.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP